Amir Fathi, MD, discusses one of the biggest nonfinancial barriers to bispecific therapies: the expertise required to safely ...

Researchers at MUSC Hollings Cancer Center have identified a signaling loop involved in the growth and persistence of ...

What will the next decade bring for myelofibrosis care? Drs Jain and Pemmaraju explore futuristic therapies, earlier ...

A patient with highly aggressive primary acute mast cell leukemia (MCL), a rare subtype of systemic mastocytosis (SM), died 3 months after her diagnosis, according to a case report published ...

The FDA has accepted the sNDA for decitabine/cedazuridine plus venetoclax to treat adults with newly diagnosed AML who are ineligible for intensive induction chemotherapy.

Ganzel C, Sun Z, Baslan T, et al: Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling. Leuk Res 123:106971, 2022 ...

Our findings suggest that certain therapy-resistant leukemia cell populations display a unique dependency on mitochondrial transcription and can be targeted with IMT. Introduction Acute myeloid ...

A.Flow cytometry analysis the proportion of myeloid cells from bone marrow, blood and ipsilateral brain after mice injection with anti-Ly6C/Ly6G at RP34D (n=4).

Acute myeloid leukemia (AML) exhibits a pronounced ability to develop drug resistance and undergo disease relapse. Recent research has noticed that resistance to treatments could substantially be ...

In this three-part webinar series, we invite you to explore the benefits of a standardized workflow in leukemia and lymphoma analysis. Join this showcase of Beckman Coulter’s new DxFLEX flow cytometer ...

A phase 1 trial evaluating SENTI-202 demonstrated positive preliminary results in treating relapsed/refractory acute myeloid leukemia.

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...